Petros Pharmaceuticals (Petros Pharmaceuticals) Change In Receivables : $0.50 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Petros Pharmaceuticals Change In Receivables?

Petros Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was $0.32 Mil. It means Petros Pharmaceuticals's Accounts Receivable declined by $0.32 Mil from Dec. 2023 to Mar. 2024 .

Petros Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.14 Mil. It means Petros Pharmaceuticals's Accounts Receivable increased by $0.14 Mil from Dec. 2022 to Dec. 2023 .

Petros Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was $1.96 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Petros Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 128.56.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Petros Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was $-6.29 Mil.

Petros Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Petros Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petros Pharmaceuticals Change In Receivables Chart

Petros Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

0.93

-2.75

2.55

0.52

-0.14

Petros Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial													-0.33	-0.15	-0.43	0.75	0.32

Petros Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.50 Mil.

Petros Pharmaceuticals (NAS:PTPI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Petros Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.957	/	1.389	*	91
=	128.56

2. In Ben Graham's calculation of liquidation value, Petros Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Petros Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	11.081	-	19.619	+	0.75 * 1.957	+	0.5 * 1.557
=	-6.29

Petros Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Petros Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petros Pharmaceuticals Inc (NAS:PTPI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036

Website

https://www.petrospharma.com

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.

Executives

Wayne Remell Walker	director	1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Greg Bradley	director	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
John D Shulman	director, 10 percent owner
Jcp Iii Sm Aiv, L.p.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, L.p.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, Ltd.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Metp Holdings Llc	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Bruce Bernstein	director	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Keith Lavan	officer: Chief Financial Officer	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Fady Boctor	officer: Pres. & Chief Comm. Officer	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Andrew Gesek	officer: President, Timm Medical	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Metuchen Therapeutics, Llc	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Mitchell Arnold	officer: Prin. Acct. Off/Prin. Fin. Off	200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726